EX-10.1 2 d492785dex101.htm EX-10.1 JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRISPR THERAPEUTICS AG CRISPR THERAPEUTICS LIMITED CRISPR THERAPEUTICS, INC....Joint Development and Commercialization Agreement • May 5th, 2020 • Massachusetts
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
BACKGROUNDJoint Development and Commercialization Agreement • August 14th, 2001 • Decode Genetics Inc • Services-commercial physical & biological research • New York
April 4, 2023Joint Development and Commercialization Agreement • April 4th, 2023
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTJoint Development and Commercialization Agreement • December 13th, 2023 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is entered into as of December 12, 2023 (the “Amendment Effective Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts, and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (together, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland, CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware, CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales, and TRACR Hematology Ltd, a UK limited company (collectively, “CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Amended
ANDJoint Development and Commercialization Agreement • March 22nd, 2000 • Signal Pharmaceuticals Inc • Services-commercial physical & biological research • California
ContractJoint Development and Commercialization Agreement • February 11th, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed.
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDMENT NO. 1 TO THE...Joint Development and Commercialization Agreement • February 15th, 2024 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is entered into as of December 12, 2023 (the “Amendment Effective Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts, and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (together, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland, CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware, CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales, and TRACR Hematology Ltd, a UK limited company (collectively, “CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Amended
AGREE ON INTENT! PDF GRATISJoint Development and Commercialization Agreement • December 21st, 2021
Exhibit September 29, The Company and the Purchaser have entered into a Joint Development and Commercialization Agreement dated as of the date hereof the Intwnt! Agreement , and together with this Agreement, the Agreements that provides, pursuant to Section 8. As a material and necessary inducement for the Company to enter into this Agreement and the Development Agreement, Laboratoire Francais du Fractionnement et des Biotechnologies, a société anonyme established under the laws of France and the sole stockholder of the Purchaser LFB has entered into a Keepwe l Agreement of even date herewith in favor of the Company the Keepwe l Agreement , and together with the Agreements, the LFB Agreements . The Purchasers obligation to purchase the First Tranche Shares sha l be subject to the satisfaction, at or before the First Tranche Closing Agrre, of each of the fo lowing conditions, provided that these conditions are for the Purchasers sole benefit and may be waived by the Purchaser at any tim
JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN GTC BIOTHERAPEUTICS, INC. AND LFB-BIOTECHNOLOGIES S.A.S.U. September 29, 2006Joint Development and Commercialization Agreement • November 3rd, 2006 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • New York
This Joint Development and Commercialization Agreement (the “Agreement”) is entered into as of September 29, 2006 (the “Effective Date”), by and between GTC Biotherapeutics, Inc., a Massachusetts corporation, having offices at 175 Crossing Boulevard, Framingham, Massachusetts 01702, USA (“GTC”), and LFB Biotechnologies S.A.S.U., a société par actions simplifiée unipersonnelle, having offices at 3, avenue des Tropiques, Les Ulis, 91958 Courtaboeuf, France (“LFB Biotech”). GTC and LFB Biotech are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND AMONG GTC BIOTHERAPEUTICS, INC. AND LFB-BIOTECHNOLOGIES S.A.S.U. AND LFB/GTC LLC AND LFB BIOTECHNOLOGIES INC. June 30, 2008Joint Development and Commercialization Agreement • August 7th, 2008 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Joint Development and Commercialization Agreement (this “Agreement”) is entered into as of June 30, 2008 (the “Restatement Date”), by and among GTC Biotherapeutics, Inc., a Massachusetts corporation, having offices at 175 Crossing Boulevard, Framingham, Massachusetts 01702, USA (“GTC”); LFB Biotechnologies S.A.S.U., a société par actions simplifiée unipersonnelle, having offices at 3, avenue des Tropiques, Les Ulis, 91958 Courtaboeuf, France (“LFB Biotech”); LFB/GTC LLC, a New York limited liability corporation, having offices at 175 Crossing Boulevard, Framingham, Massachusetts 01702, USA (“LFB/GTC LLC”) and LFB Biotechnologies Inc., a Delaware corporation having a registered office at 2711 Centerville Road, Suite 400, Wilmington, Delaware (“LFB-US”). GTC, LFB Biotech, LFB-US and LFB/GTC LLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDED AND RESTATED JOINT...Joint Development and Commercialization Agreement • July 30th, 2021 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of April 16, 2021 (the “Amendment Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales (“CRISPR UK”), and TRACR Hematology Ltd, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK, “CRISPR”), and amends and restates that ce
AMENDED AND RESTATED Joint Development and Commercialization AGREEMENT BETWEENJoint Development and Commercialization Agreement • April 27th, 2021 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of April 16, 2021 (the “Amendment Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales (“CRISPR UK”), and TRACR Hematology Ltd, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK, “CRISPR”), and amends and restates that ce
